Response to the Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma”

Saved in:
Bibliographic Details
Published inLeukemia Vol. 33; no. 5; pp. 1301 - 1302
Main Authors Barosi, Giovanni, Gale, Robert Peter
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.05.2019
Nature Publishing Group
Subjects
631/67/1059
692/700/565
Autografts
Cancer patients
Cancer Research
Critical Care Medicine
Dosage and administration
Drug therapy
Health aspects
Hematology
Humans
Intensive
Internal Medicine
Lenalidomide
Letter
Medicine
Medicine & Public Health
Multiple Myeloma
Myeloma
Oncology
Retirement benefits
Risk factors
Thalidomide
Transplantation, Autologous
Online AccessGet full text

Cover

More Information
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-019-0432-x